-
公开(公告)号：EP3870148A1
公开(公告)日：2021-09-01
申请号：EP19876857.4
申请日：2019-10-24
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： CHOI, Vivian , LI, Xing
-
公开(公告)号：EP3820490A1
公开(公告)日：2021-05-19
申请号：EP19833959.0
申请日：2019-07-11
申请人： Baxalta Incorporated , Baxalta GmbH
-
公开(公告)号：EP3705133A2
公开(公告)日：2020-09-09
申请号：EP19217974.5
申请日：2011-05-13
申请人： Baxalta Incorporated , Baxalta GmbH , The Research Foundation for The State University of New York , Brookhaven Science Associates LLC
发明人： Crowe, Brian A. , Dr. Livey, Ian , O'Rourke, Maria , Schwendinger, Michael , Dunn, John J. , Luft, Benjamiin J.
摘要： The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.
-
公开(公告)号：EP3650041A1
公开(公告)日：2020-05-13
申请号：EP19201651.7
申请日：2011-05-13
申请人： Baxalta Incorporated , Baxalta GmbH
摘要： The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.
-
公开(公告)号：EP3121266B8
公开(公告)日：2020-04-22
申请号：EP16183987.3
申请日：2007-01-03
申请人： Baxalta Incorporated , Baxalta GmbH
IPC分类号： C12N5/00
-
6.发明公开
公开(公告)号：EP3594686A3
公开(公告)日：2020-04-08
申请号：EP19174514.0
申请日：2013-08-12
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： DOCKAL, Michael , SCHEIFLINGER, Friedrich , ZHANG, Zhenqing , TILL, Susanne , KNAPPE, Sabine , SZABO, Christina
摘要： Aspects of the invention include methods for identifying one or more NASP (non-anticoagulant sulfated polysaccharide) compositions that are suitable for treating a subject having a blood coagulation disorder. In practicing methods according to certain embodiments, NASP compositions are evaluated by determining the coagulation activity and chemical makeup of the NASP composition and the molecular structure of the NASP. Systems for practicing methods of the invention as well as compositions suitable for treating a subject having a blood coagulation disorder are also described.
-
公开(公告)号：EP3620177A1
公开(公告)日：2020-03-11
申请号：EP19189998.8
申请日：2009-10-16
申请人： Baxalta GmbH , Baxalta Incorporated
摘要： The present invention relates, in general, to materials and methods for the preparation of modified blood factors which have low levels of water soluble polymer molecules conjugated to the blood factor but exhibit biological activity similar to or better than molecules having a higher number of water soluble polymer moieties.
-
8.发明公开
公开(公告)号：EP3597220A1
公开(公告)日：2020-01-22
申请号：EP19197257.9
申请日：2014-02-25
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： Frey, William, H. , Hanson, Leah Ranae, Bresin , Pokropinski, Sharon , Rausa III, Francisco, M.
IPC分类号： A61K39/395 , A61K9/00
摘要： The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
-
公开(公告)号：EP3590960A1
公开(公告)日：2020-01-08
申请号：EP19180237.0
申请日：2013-02-28
申请人： Baxalta GmbH , Baxalta Incorporated
发明人： Kuery, Patrick , Tzekova, Nevena , Hartung, Hans-Peter , Hermann, Corinna , Reipert, Birgit Maria , Schwarz, Hans-Peter , Ehrlich, Hartmut , Bunk, Sebastian
摘要： The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
-
公开(公告)号：EP3569216A1
公开(公告)日：2019-11-20
申请号：EP19169568.3
申请日：2016-06-17
申请人： Baxalta Incorporated , Baxalta GmbH
发明人： SCHWEISS,, Mark David , ROUSH,, Daniel E. , HOLZNER,, Stefan , JONES,, Seth Dale , LOOPER,, Anthony Martin , DHYANI,, Tejas , SHAH,, Michelle , GIBSON,, Madeleine Clare , CHUNG,, Jessica
摘要： A device [10] is provided for pooling a fluid from a container unit [12] having at least one container [14, 16], and includes an inlet port [18] having at least one inlet channel [22, 24] configured for receiving the fluid or ambient air, and an outlet port [26] having at least one outlet channel [32, 34] configured for delivering the fluid to an attachment. Both inlet and outlet ports [18, 26] are disposed on the device [10]. A cavity [40] is provided for accommodating insertion of the container unit [12] for pooling the fluid from the at least one container [14, 16]. At least one spike [48, 50] is disposed in the cavity and configured for puncturing a stopper [44, 46] of the at least one container when the container unit transitions from an upper position to a lower position.
-
-
-
-
-
-
-
-
-
搜索结果
206 条记录 (耗时 0.035 秒)
